
RESULTS OF LIQUID BIOPSY STUDIES BY NEXT
GENERATION SEQUENCING IN PATIENTS WITH
ADVANCED STAGE NON-SMALL CELL LUNG CANCER:
SINGLE CENTER EXPERIENCE FROM TURKEY Buyuksimsek M1,*, Togun M2, Oguz Kara I1, Bisgin A3,4, Boga I4, Tohumcuoglu M1,
Ogul A1, Evren Yetisir A1, Sahin B1, Erdem Sumbul H5, Mirili C6 *Corresponding Author: Mahmut Buyuksimsek, M.D., Department of Oncology, Çukurova University
Faculty of Medicine, Sarican, Adana, Turkey. Tel: +90-536-862-20-26. Fax: +90-322-338-70-72.
E-mail: mahmutbuyuksimsek@gmail.com page: 17 download article in pdf format
|
Abstract
Several studies demonstrated the utility of plasmabased
cell-free circulating tumor DNA (ccfDNA) in determination
of mutations in non-small cell lung cancer (NSCLC).
We aimed to report our results of next generation sequencing
(NGS) using liquid biopsy in patients with NSCLC. Patients
with advanced stage NSCLC were enrolled and their
genomic profiling results were recorded. Next generation
sequencing targeted panel includes 19 hot-spot genes. The
plasma was separated from the peripheral blood sample and
ccfDNAs were isolated for NGS. We performed genomic
profiling in 100 patients (20 females and 80 males) with a
median age of 59.3 (range 26-79). A second liquid biopsy
was performed in eight patients who developed progressive
disease after the first treatment. The study population had
adenocarcinoma (AC) (n = 73), squamous cell carcinoma
(SCC) (n = 14), or NSCLC-NOS (not otherwise specified)
(n = 13). In the SCC group, three of 14 patients had variants
on EGFR and MET genes. In the AC and NSCLC-NOS
groups, 39 out of 86 patients (45.3%) had variants. The
most common one was in the EGFR gene (n = 27, 31.4%)
including seven mutations related to drug resistance and
two were polymorphisms. Three patients had both driver
and resistance mutations (EGFR T790M, n = 2; KRAS exon
2 G12S and MET exon 14 E1012K, n = 1). Fifteen patients
(17.4%) had an activating EGFR mutation and eight patients
(9.3%) had variants in the KRAS gene. We reported
our results regarding genomic profiling related to treatment
using liquid biopsy in patients with NSCLC. Advantages of
this method are the non invasiveness and reproducibility.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|